| 1 |
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death
Kageaki Kuribayashi, Gabriel S. Krigsfeld, Wenge Wang et al. · Cancer Biology & Therapy
Open access |
Dec 2008 |
131 |
| 2 |
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
Robert Spiera, Laura Kathleen Hummers, Lorinda Chung et al. · Arthritis & Rheumatology
Open access |
26 Apr 2020 |
104 |
| 3 |
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
Elena Schiopu, Soumya Swarup Chatterjee, Vivien M Hsu et al. · Arthritis Research & Therapy
Open access |
7 Jun 2016 |
82 |
| 4 |
Potent Anti‐Inflammatory and Pro‐Resolving Effects of Anabasum in a Human Model of Self‐Resolving Acute Inflammation
Madhur P. Motwani, Frances Jenkins Bennett, Paul C. Norris et al. · Clinical Pharmacology & Therapeutics
Open access |
14 Dec 2017 |
76 |
| 5 |
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis
James F. Chmiel, Patrick A. Flume, Damian G. Downey et al. · Journal of Cystic Fibrosis
Open access |
Oct 2020 |
68 |
| 6 |
Encoding of images based on a lapped orthogonal transform
Philippe M. Cassereau, D. H. Staelin, Gerhard De Jager · IEEE Transactions on Communications
|
1989 |
61 |
| 7 |
Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity
Mark A. Tepper, Robert B. Zurier, SUMNER H. BURSTEIN · Bioorganic & Medicinal Chemistry
Open access |
9 May 2014 |
58 |
| 8 |
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial
Victoria P. Werth, Emily Z. Hejazi, Sandra M. Pena et al. · Journal of Investigative Dermatology
Open access |
28 Apr 2022 |
54 |
| 9 |
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis
Robert Spiera et al. · Arthritis & Rheumatology
Open access |
26 Apr 2023 |
44 |
| 10 |
Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness
Kristen L. Chen, Jay Patel, Majid Zeidi et al. · Journal of Investigative Dermatology
Open access |
5 Mar 2021 |
32 |
| 11 |
Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile
Yuval Cohen, Andrew Kolodziej, Marshall Morningstar · Obesity
Open access |
17 Jun 2024 |
25 |
| 12 |
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM
Spandana Maddukuri, Jay Patel, DeAnna Diaz et al. · Arthritis Research & Therapy
Open access |
4 Jan 2022 |
25 |
| 13 |
Novel cannabinoid receptor 1 inverse agonist CRB ‐913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet‐induced obesity mouse model
Marshall Morningstar, Andrew Kolodziej, Suzie A. Ferreira et al. · Obesity
Open access |
16 Oct 2023 |
24 |
| 14 |
Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling
Nelson E. Bruno, Jerome C. Nwachukwu, Sathish Srinivasan et al. · Nature Chemical Biology
Open access |
28 Jan 2021 |
24 |
| 15 |
FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis
Victoria P. Werth, Emily Z. Hejazi, Sandra M. Pena et al. · Annals of the Rheumatic Diseases
Open access |
Jun 2018 |
22 |
| 16 |
Potent T cell‐mediated anti‐inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis
Marta Tiberi, Tama Evron, Stefano Saracini et al. · Neuropathology and Applied Neurobiology
|
20 Sep 2021 |
21 |
| 17 |
Anti-inflammatory effects of lenabasum, a cannabinoid receptor type 2 agonist, on macrophages from cystic fibrosis
Abdullah A. Tarique, Tama Evron, George Zhang et al. · Journal of Cystic Fibrosis
Open access |
6 May 2020 |
20 |
| 18 |
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale
Robert Spiera, Dinesh Khanna, Masataka Kuwana et al. · Clinical and Experimental Rheumatology
Open access |
28 Jul 2021 |
19 |
| 19 |
Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial
Rachita Pandya, Joshua Dan, Julianne Kleitsch et al. · Journal of Investigative Dermatology
Open access |
16 Jun 2023 |
13 |
| 20 |
Effects of Formulation Variables on Lung Dosimetry of Albuterol Sulfate Suspension and Beclomethasone Dipropionate Solution Metered Dose Inhalers
Jeffry D. Schroeter, Poonam Sheth, Anthony James Hickey et al. · AAPS PharmSciTech
|
Jun 2018 |
13 |
| 21 |
Code design and performance characterization for code multiplexed imaging
Jules S. Jaffe, Philippe M. Cassereau, D.J. Glassbrenner · IEEE Transactions on Acoustics Speech and Signal Processing
|
1990 |
13 |
| 22 |
OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)
Robert Spiera, Masataka Kuwana, Dinesh Khanna et al. · Annals of the Rheumatic Diseases
Open access |
25 May 2021 |
11 |
| 23 |
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis
BARBARA W. WHITE, Daniel E. Furst, Tracy Frech et al. · ACR Open Rheumatology
Open access |
Mar 2025 |
9 |
| 24 |
FRI0307 LENABASUM, A CANNABINOID TYPE 2 RECEPTOR AGONIST, REDUCES CD4 CELL POPULATIONS AND DOWNREGULATES TYPE 1 AND 2 INTERFERON ACTIVITIES IN LESIONAL DERMATOMYOSITIS SKIN
Kristen Chen, Majid Zeidi, Nithin D. Reddy et al. · Annals of the Rheumatic Diseases
Open access |
Jun 2019 |
9 |
| 25 |
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study
Caroline J. Stone, Geeta Ahuja, Laís Lopes Almeida Gomes et al. · JID Innovations
Open access |
6 Sep 2024 |
6 |
| 26 |
Preclinical mitigation of 5-HT2B agonism-related cardiac valvulopathy revisited
Berengere M Dumotier, László Urbán · Journal of Pharmacological and Toxicological Methods
|
Jul 2024 |
6 |
| 27 |
610 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated on an open-label extension of trial JBT101-DM-001
Victoria P. Werth, David R. Pearson, Joyce Okawa et al. · Journal of Investigative Dermatology
Open access |
19 Apr 2019 |
6 |
| 28 |
Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis
Natalie E. West et al. · Journal of Cystic Fibrosis
|
26 May 2025 |
5 |
| 29 |
Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials
Rachita Pandya, Joshua Dan, Julianne Kleitsch et al. · JID Innovations
Open access |
10 Dec 2024 |
5 |
| 30 |
605 Study of safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis
V. Werth, Emily Z. Hejazi, Sandra M. Pena et al. · Journal of Investigative Dermatology
Open access |
19 Apr 2018 |
5 |
| 31 |
Lenabasum Reduces Porphyromonas gingivalis–Driven Inflammation
Fareeha Batool, Pierre‐Yves Gegout, Céline Stutz et al. · Inflammation
|
11 Mar 2022 |
4 |
| 32 |
Incoherent coding techniques and performance characterization for multibeam sonar systems
Jules S. Jaffe, D.J. Glassbrenner, Philippe M. Cassereau
Conference paper |
6 Jan 2003 |
4 |
| 33 |
Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist
Rachel R. Luba, Gabriela Madera, Rebecca Schusterman et al. · Journal of Pharmacology and Experimental Therapeutics
Open access |
27 Jun 2024 |
2 |
| 34 |
068 Lenabasum reduces IFNγ and pIRF3 in dermatomyositis skin: Biomarker results from a double-blind phase 3 international randomized controlled trial
Thomas Vazquez, M. Sharma, R. Feng et al. · Journal of Investigative Dermatology
Open access |
20 Jul 2022 |
2 |
| 35 |
967P Phase I/II study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours
Cesar A. Perez, Charlene M. Mantia, Allen Lee Cohn et al. · Annals of Oncology
Open access |
Sep 2025 |
1 |
| 36 |
A Physiologically Based Pharmacokinetic and Drug–Drug Interaction Model for the CB2 Agonist Lenabasum
Qiang Fu, Hannah M. Jones, Gang Sun et al. · European Journal of Drug Metabolism and Pharmacokinetics
|
18 Jun 2021 |
1 |
| 37 |
Genetic Instability and Chronic Inflammation in Gastrointestinal Cancers
Antonia R. Sepulveda, John Patrick Lynch
Book chapter |
28 Aug 2009 |
1 |
| 38 |
CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
Zhaopeng Sun, Mo Dan, Lu Lv et al. · Cancer Research Communications
Open access |
24 Aug 2026 |
0 |
| 39 |
Revolutionizing the Strategic Advantage: The Future of Intelligent Supply Chains
Pratibha Pandey, Anamika Pandey, Ashutosh Kumar Pandey
Book chapter |
18 Mar 2025 |
0 |
| 40 |
440 CDASI-activity vs IGA scores for dermatomyositis in the lenabasum phase 3 trial
R. Pandya, J. Dan, J. Kleitsch et al. · Journal of Investigative Dermatology
Open access |
17 Apr 2023 |
0 |
| 41 |
521 The total improvement score (TIS) in a phase 3 clinical trial for dermatomyositis (DM): Room for improvement?
J. Dan, D. Lim, R. Pandya et al. · Journal of Investigative Dermatology
Open access |
17 Apr 2023 |
0 |
| 42 |
238 Cutaneous dermatomyositis area and severity index activity score (CDASI-A) and associated patient-reported outcomes in a phase 2 clinical trial in dermatomyositis
Josh Dan, Josef Symon S. Concha, Grant Sprow et al. · Journal of Investigative Dermatology
Open access |
20 Jul 2022 |
0 |
| 43 |
Acyl Glucuronide of Oxidized Lenabasum (JBT‐101) as Human Major Metabolite: Identification, Large‐Scale Synthesis, and Activity Characterization
Hongfeng Deng, Clifton D. Leigh, Yun Yang et al. · ChemistrySelect
|
10 Nov 2021 |
0 |
| 44 |
AB018. Myeloid dendritic cells (mDCs) are major producers of interferon-beta in dermatomyositis and increased numbers of mDCs are found in hydroxychloroquine nonresponders
Kristen L. Chen, Majid Zeidi, Maria Wysocka et al. · Annals of Translational Medicine
Open access |
Mar 2021 |
0 |
| 45 |
Proceedings of the 2019 Canadian Inflammatory Myopathy Study Symposium: Clinical Trial Readiness in Myositis
Valérie Leclair, Océane Landon‐Cardinal, Rohit Aggarwal et al. · The Journal of Rheumatology
Open access |
15 Jun 2020 |
0 |